HER2 mutations in patients with HER2 amplification-negative breast cancer had a higher frequency of HER2 hotspot mutations than in patients with HER2 amplification-positive breast cancer (36.5%, 19/52 vs. 5.0%, 24/477; P < 0.001). Here, ERBB2 is linked to breast carcinoma.